We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Barr Laboratories has received final approval from the FDA to market its generic version of Aventis Pharmaceuticals' Allegra (fexofenadine HCl) capsules in a 60-mg dosage strength.
InterMune and Array BioPharma have announced the extension and expansion of their current collaboration to discover and develop novel small molecule inhibitors of the hepatitis C virus (HCV) NS3/4 protease.
Nutrition 21 reported results from a new clinical study that add to the growing body of clinical data demonstrating that daily supplementation with Diachrome, a combination of chromium picolinate and biotin, can significantly reduce cardiovascular disease risk factors in people with Type 2 diabetes.
Gilead Sciences has begun enrolling patients in its Phase III clinical program evaluating the oral antiviral drug tenofovir disoproxil fumarate (tenofovir DF) for the treatment of chronic hepatitis B.
Biogen and Elan Corporation have announced that SENTINEL, the Phase III Tysabri (natalizumab) add-on trial with Avonex (Interferon beta-1a), slowed the progression of disability in patients with relapsing forms of multiple sclerosis (MS).
Cobalis, a pharmaceutical biotech company specializing in the development of anti-allergy medications, announced that preliminary analyses performed on data collected during their first Phase III trial for its flagship anti-allergy medication PreHistin has demonstrated that pre-seasonal treatment with the drug reducesn allergy symptoms.
Human Genome Sciences reported that results published in the current issue of
Clinical Infectious Diseases demonstrate that the first investigational agent
against anthrax infection to be evaluated in a clinical study since the 2001
anthrax attacks in the U.S., is safe, well-tolerated and achieves the blood
levels predicted by relevant animal models as necessary to afford significant
protection from the lethal effects of the anthrax toxin.